Idera to Present at the Stifel 2016 Healthcare Conference

CAMBRIDGE, Mass. and EXTON, Pa., Nov. 10, 2016 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. IDRA, a clinical-stage biopharmaceutical company developing toll-like receptor and RNA therapeutics for patients with cancer and rare diseases, today announced that Idera's Chief Executive Officer, Vincent Milano will provide a corporate overview the Stifel 2016 Healthcare Conference on Wednesday November 16, 2016 at 3:00 p.m. Eastern Time at the Lotte New York Palace Hotel.

Live audio webcast of Idera's presentations will be accessible in the Investors and Media section of Idera's website at http://www.iderapharma.com. Archived versions will also be available on the Company's website after the event for 90 days. 

About Idera Pharmaceuticals
Idera Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel nucleic acid-based therapies for the treatment of certain cancers and rare diseases. Idera's proprietary technology involves designing synthetic oligonucleotide-based drug candidates to modulate the activity of specific TLRs. In addition to its TLR programs, Idera has used its proprietary knowledge to create a third generation antisense technology platform which inhibits the production of disease-associated proteins by targeting RNA. To learn more about Idera, visit www.iderapharma.com.

Investor and Media Contact Robert Doody VP, IR & Corporate Communications 617-679-5515 (office) 484‐639‐7235 (mobile) rdoody@iderapharma.com

Primary Logo

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: Press Releases
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!